Evaluate the Post-marketing Efficacy and Safety of Eptq S and Eptq Lidocaine S

Exclusion Criteria

• •Received anti-thrombotics (except low-dose aspirin \[100 mg, maximum 300 mg/day\]) within 2 weeks from screening.
• •Currently have or have a history of bleeding disorder.
• •applied graft/prosthesis or biomaterials, including hyaluronic acid, polycaprolactone, collagen filler, lifting (threads, laser, etc.), and Botulinum toxin, at the site for indication within 24 weeks from screening.
• •Skin disorder or wound infection on the face that affects this study
• •Have history of side effects of EMLA cream or equivalent lidocaine agent.
• •History of hypersensitivity to hyaluronic acid agent(s).
• •Other contraindications as per the \[Precautions for Use\] in the approved label for the study device.